Experts mull effect of isotope bill on diagnostic imaging industry

01/24/2013 | Diagnostic Imaging

President Barack Obama recently signed the American Medical Isotope Production Act of 2011, which promotes domestic production of low-enriched uranium-based isotopes, and industry experts are weighing the effect of this on the diagnostic imaging field. Colleen Glynn, senior marketing director for the Nuclear Pharmacy Services Business of Cardinal Health, said the use of LEU is not new, as it has long been the normal practice to use a blend of LEU- and highly enriched uranium-based molybdenum-99. Lynn Phillips of Covidien's pharmaceutical unit Mallinckrodt said the subsidiary can produce LEU-derived technetium-99m generators that comply with CMS criteria, but clients have yet to ask for them.

View Full Article in:

Diagnostic Imaging

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park